Results 91 to 100 of about 99,677 (264)

Subcutaneous tocilizumab treatment in patients with severe COVID-19–related cytokine release syndrome: An observational cohort study

EClinicalMedicine, 2020
Background: Patients with severe coronavirus disease 2019 (COVID-19) have elevated levels of acute phase reactants and inflammatory cytokines, including interleukin-6, indicative of cytokine release syndrome (CRS).
Antonio Mastroianni, Sonia Greco, Giovanni Apuzzo, Salvatore De Santis, Carmela Oriolo, Alfredo Zanolini, Luciana Chidichimo, Valeria Vangeli   +7 more
doaj   +1 more source

Myelitis‐Predominant Aggressive Phenotype: Unveiling Unique Patterns of Late‐Onset Neuromyelitis Optica Spectrum Disorders

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare clinical features and prognosis of late‐onset neuromyelitis optica spectrum disorder (LO‐NMOSD, onset age ≥60 years) with adult‐onset NMOSD (AO‐NMOSD, onset age 18–59 years), and to provide insights for individualized management in elderly patients.
Ya‐Lan Pu, Jin‐Zhou Feng, Hua‐Xing Meng, Hai‐Bing Xiao, Xiao‐Ling Li, Jin Zhen, Wen‐Ying Lu, Xu‐Ming Xi, Ti Wu, Bao‐Shi Yuan, Mo‐Li Fan, Chao Zhang, De‐Cai Tian, Xia Meng, Fu‐Dong Shi, Tian Song   +15 more
wiley   +1 more source

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis? [PDF]

, 2017
Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA).
A Ferreiro-Iglesias, A Groof De, A Kavanaugh, A Montes Marquez, a N Burska, A Obry, A Pachot, A Picchianti Diamanti, A Ruyssen-Witrand, AP Treschow, AP Trouvin, B Bresnihan, B Mesko, B Möller, BVJ Cuppen, C a Wijbrandts, C Castro-Villegas, C Enevold, C Potter, C Trocmé, CM Weyand, CP Mavragani, D Plant, D Plant, D Plant, D-Y Chen, DA Pappas, DF McWilliams, DS Gibson, Edward M. Vital, EM Vital, F Breedveld, G Dennis, G Dennis Jr, G Ferraccioli, G Morozzi, GS Firestein, H Canhão, H Marotte, H-P Brezinschek, HG Raterman, HL Wright, I Acosta-Colman, I González-Alvaro, I Gutierrez-Roelens, I Ortea, I Ortea, IY Choi, J Adriaansen, J Cui, J Ducreux, J Holten van, J Holten van, J Inciarte-Mundo, J Kikuchi, J Oliver, J Pieper, J Sellam, J Sellam, J Sellam, J Sellam, J Wang, J Wang, JAB Nies van, JD Cañete, JD Isaacs, JE Gottenberg, JL Nam, João Eurico Fonseca, JT Joensuu, JW Whitaker, K Chatzidionysiou, K Hambardzumyan, K Kayakabe, K Klein, K Owczarczyk, K Shimamoto, K Uno, K Vos, KL Hyrich, KL Hyrich, L Mancarella, LE Kristensen, LG Baarsen van, LGM Baarsen Van, M Abildtrup, M Ammari, M Nakou, M Scarsi, M Scarsi, M Umemura, Maya H. Buch, MH Buch, MH Buch, MH Buch, MH Stradner, MJ Leandro, MJ Townsend, MK Crow, MK Söderlin, P Roll, PA Schouwenburg van, PP Tak, R Klaasen, R Priori, RJ Maneiro, RM Thurlings, RM Thurlings, S Alzabin, S Das, S Dass, S Fabre, S Fabre, S Iwata, S Kelly, S Kubo, S Nakamura, S Rosengren, S Saevarsdottir, S Visvanathan, S Visvanathan, S Vosslamber, S-Y Kawashiri, SB Krintel, SC Nair, SK Sieberts, SL Smith, SL Smith, SR Kapoor, TC Pouw Kraan van der, TJM Smeets, U Meusch, V Badot, Vasco C. Romão, VE Hogan, W Hueber, Y Sanayama, Y-M Pers, YH Lee, YKO Teng, Z Mahmood   +140 more
core   +3 more sources

Facilitating Expedited Drug Approval– the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, Accepted Article.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source

Defining the optimal biological monotherapy in rheumatoid arthritis: a systematic review and meta-analysis of randomised trials [PDF]

, 2016
Objectives To summarize and compare the benefits and harms of biological agents used as monotherapy for rheumatoid arthritis (RA) in order to inform decisions for patients who are intolerant to conventional DMARD therapy.
Bliddal, Henning, Boers, Maarten, Choy, Ernest Ho Sing, Christensen, Robin, Dossing, Anna, Furst, Daniel E., Hansen, Michael S., Kristensen, Lars E., Lorenzen, Tove, Singh, Jasvinder A., Suarez-Almazor, Maria E., Tarp, Simon, Østergaard, Mikkel   +12 more
core   +2 more sources

Tocilizumab as a targeted immunomodulatory therapy in the management of severe respiratory illnesses: a multicenter cohort study of COVID-19 patients

Scientific Reports
Respiratory pandemics like COVID-19 continued to strain healthcare systems worldwide. Numerous antiviral, antimalarial, and anti-inflammatory treatments were administered to many patients to pursue effective therapeutics.
Abbas Al Mutair, Saad Alhumaid, Gasmelseed Y. Ahmad, Ali A. Rabaan, Sameer A. Alkubati, Hamdan Albaqawi, Awatif M. Alrasheeday, Bushra Alshammari, Kawther Alsaleh, Richard Mottershead, Muhammad Daniyal, Awad Al-Omari   +11 more
doaj   +1 more source

Interleukin‐18 Levels Are Associated With Disease Course in Patients With Still Disease Treated With Interleukin‐1 Inhibitors

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the prognostic utility of circulating interleukin‐18 (IL‐18) levels in predicting disease activity, macrophage activation syndrome (MAS), and disease course in patients with Still disease (SD) receiving first‐line IL‐1 inhibitors (IL‐1i).
Matteo Trevisan, Manuela Pardeo, Ivan Caiello, Claudia Bracaglia, Arianna De Matteis, Valentina Matteo, Elena Loricchio, Fabrizio De Benedetti, Giusi Prencipe   +8 more
wiley   +1 more source

Interferon-beta-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab [PDF]

, 2014
Background: Neuromyelitis optica (NMO) is a severely disabling inflammatory disorder of the central nervous system and is often misdiagnosed as multiple sclerosis (MS).
Aktas, Orhan, Goebels, Norbert, Harmel, Jens, Hartung, Hans-Peter, Ingwersen, Jens, Jarius, Sven, Mathys, Christian, Ringelstein, Marius   +7 more
core   +1 more source